Scarring data update boosts battered Renovo shares

After seeing its stock price hammered in March on mixed data for the scarring drug Juvista, the UK's Renovo has seen shares bounce back on the news that two more mid-stage studies have produced positive results. And Renovo says it's now poised to begin its first late-stage trial this year. So far, Renovo has mounted 16 early and mid-stage trials of Juvista.

The new results came from a planned 12 month follow-up analysis of two Juvista (human recombinant TGFβ3) Phase II clinical trials: RN1001-0050 and RN1001-0036. Analysis of 12 month data supports a previously stated efficacious dosage window of 50-500ng/100uL/linear cm and researchers concluded that the greatest magnitude of scar improvement effect was seen in 500ng/100uL/linear cm dosed twice, 24 hours apart.

Renovo stock lost half of its value in March, a sign to some analysts of the bipolar mood that influences biotech stock prices.

- see this release
- read the report in Hemscott

Related Articles:
Renovo shares plunge even after 'buy' signals. Stock report
Mixed data for Renovo's scarring therapy. Justiva report
Renovo inks $875M deal for scarring drug. Renovo report
Renovo CEO bullish on partnership prospects. Renovo report

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.